BioSpace News Archive

The checkpoint inhibitor is approved for several cancers in China, but after an indefinite FDA delay last summer, BeiGene’s partner Novartis still awaits its first U.S. approval.

Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone.

Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.

The deal could be worth more than $1 billion, starting with an upfront payment of $22.75 million.

Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.

BioInvent International AB announces that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma.

Sofinnova Partners announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team.

Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed generic drug product in a class of medications called antimetabolites.

Augmedix today announced a partnership with HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, to accelerate development of technology that aims to transform the way patient care is documented in the acute care setting.